Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websitenanobio.com
Twitter@nanobio
CategoryBioTech
Emailjohn.coffey@nanob...
Employees
Founded2000
DescriptionMedical Treatments

Offices

Ann Arbor, USA
2311 Green Road
Suite A
Ann Arbor, MI, 48105
USA

People

CEO & Member Of The Board Of Directors
Vice President, Clinical Research
Vice President, Regulatory Affairs
Sr. Vice President, Vaccine Research & Development
Sr. Vice President, Development
Member Of The Board Of Directors
Member Of The Board Of Directors
Member Of The Board Of Directors
Show All People

Funding

TOTAL $39M
FUNDING TOTAL $39M
Series B, 7/2009
Perseus
$22M
Grant, 11/2010
Bill & Melinda Gates Foundation
$6M
Series C, 11/2012
$11M

Tags

NanoBio

NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, based on its patented NanoStat™ technology platform.

Founded in 2000 as a spin-out from the Center for Biologic Nanotechnology at the University of Michigan, NanoBio’s lead product candidates target treatments for herpes labialis (cold sores), onychomycosis (nail fungus), vaginitis, cystic fibrosis and intranasal & intramuscular vaccines for influenza, RSV, HSV2 and anthrax.

Recent Milestones

Videos

Screenshots

NanoBio screenshot
Above: NanoBio Screenshot -- #1
Uploaded: 7/8/09

Sources

  1. NanoBio tops up $22M round as it closes in on pact (fiercebiotech.com) [edit]
  2. NanoBio Receives $6 Million to Develop an Intranasal Vaccine for Respiratory Syncytial Virus (RSV) (nanobio.com) [edit]
  3. NanoBio® Closes $11 Million Series C Financing (businesswire.com) [edit]
Edit This Page
Last Edited 1/13/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy